Continuous-infusion doxorubicin in the treatment of primary hepatic malignancies of childhood

J. P. Neglia, W. G. Woods

Research output: Contribution to journalArticlepeer-review

19 Scopus citations

Abstract

Five children with primary hepatic malignancies were treated with continuous infusions of doxorubicin administered as a single agent every 3-4 weeks. Four of five children showed positive response to therapy, manifested by decreasing tumor size and/or tumor markers; the fifth child had stable disease for 4 months. Side effects included mild nausea and vomiting and myelosuppression. No evidence of cardiotoxicity was seen with cumulative doses up to 720 mg/m2.

Original languageEnglish (US)
Pages (from-to)655-657
Number of pages3
JournalCancer Treatment Reports
Volume70
Issue number5
StatePublished - 1986

Fingerprint Dive into the research topics of 'Continuous-infusion doxorubicin in the treatment of primary hepatic malignancies of childhood'. Together they form a unique fingerprint.

Cite this